Vivo Capital (“Vivo” or “the Firm”), a leading global investment firm focused exclusively on healthcare and life sciences, has closed the third cycle of its Vivo Opportunity Fund and its affiliates (the “Public Fund”) with over $740 million in commitments. The Public Fund invests in preclinical and clinical stage life sciences businesses that are developing or commercializing novel therapies for unmet medical needs. Vivo Opportunity Fund is an evergreen fund with three-year investment cycles. The third cycle of Vivo Opportunity Fund will follow the same strategy as its first and second cycles, leveraging Vivo’s deep scientific and technical capabilities to invest in small- and mid-cap biotechnology and life sciences companies.
Read the full article: Vivo Capital Closes Its Public Fund with Commitments of Over $740M //
Source: https://www.businesswire.com/news/home/20250507646594/en/Vivo-Capital-Closes-Its-Public-Fund-with-Commitments-of-Over-%24740-Million